NEUROVASCULAR clinical

Learn more about our ongoing commitment to research.

GLOBAL TIMELINE

SUPPORTING 47+ CLINICAL STUDIES

We use research to validate product safety and efficacy, improve patient outcomes, establish guidelines and quality metrics, demonstrate economic viability and increase patient access to the right therapy.

STROKE
THERAPY

stroke therapy

ROBUST DATA FOR
SAFETY AND EFFICACY

The New England Journal of Medicine has featured the first-of-its-kind Solitaire™ thrombectomy device 5 times. Solitaire is designed to remove a clot and reduce stroke-related disability in patients suffering from AIS with large-vessel occlusion following IV t-PA.

see the evidence
LEARN ABOUT SOLITAIRE

ANEURYSM
THERAPY

syringe still from aneurysm therapy

MOST STUDIED FLOW
DIVERTER WORLDWIDE1,2

Proven to provide over 95% occlusion and 0% recurrence at 5 years for patients with follow-up3, Pipeline™ embolization device is the first flow diversion device approved by the FDA for its safety and efficacy. Today, with over 5 years of clinical research, it’s still the most studied flow diverter worldwide.

VIEW THE DATA
LEARN ABOUT PIPELINE

want to
return to neurovascular?

go to neurovascular
DOCTORS WALKING

ANY QUESTIONS?

Do you need support for procedures? Or information on our products and solutions?

Our team is happy to help answer any questions you may have.

CONTACT US
1

PMA- P100018-S011

2

Scientific Communication Document search (2018) showing clinical summaries. No other studies meet these criteria.

3

Becske T. et al., Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms: Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms Trial., (JNS) Neurosurgery Published online Jan 9, 2017.